Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.91
ABT's Cash to Debt is ranked higher than
62% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. ABT: 0.91 )
ABT' s 10-Year Cash to Debt Range
Min: 0.05   Max: 1.23
Current: 0.91

0.05
1.23
Equity to Asset 0.56
ABT's Equity to Asset is ranked higher than
64% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. ABT: 0.56 )
ABT' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.59
Current: 0.56

0.37
0.59
Interest Coverage 16.75
ABT's Interest Coverage is ranked higher than
58% of the 449 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. ABT: 16.75 )
ABT' s 10-Year Interest Coverage Range
Min: 4.91   Max: 34.27
Current: 16.75

4.91
34.27
F-Score: 5
Z-Score: 3.74
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 12.03
ABT's Operating margin (%) is ranked higher than
78% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. ABT: 12.03 )
ABT' s 10-Year Operating margin (%) Range
Min: 8.81   Max: 24.91
Current: 12.03

8.81
24.91
Net-margin (%) 11.79
ABT's Net-margin (%) is ranked higher than
82% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. ABT: 11.79 )
ABT' s 10-Year Net-margin (%) Range
Min: 7.64   Max: 27.74
Current: 11.79

7.64
27.74
ROE (%) 10.23
ABT's ROE (%) is ranked higher than
81% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. ABT: 10.23 )
ABT' s 10-Year ROE (%) Range
Min: 10.23   Max: 41.59
Current: 10.23

10.23
41.59
ROA (%) 6.00
ABT's ROA (%) is ranked higher than
80% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.09 vs. ABT: 6.00 )
ABT' s 10-Year ROA (%) Range
Min: 4.75   Max: 18.23
Current: 6

4.75
18.23
ROC (Joel Greenblatt) (%) 24.52
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.47 vs. ABT: 24.52 )
ABT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 14.22   Max: 55.16
Current: 24.52

14.22
55.16
Revenue Growth (%) -15.00
ABT's Revenue Growth (%) is ranked higher than
50% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ABT: -15.00 )
ABT' s 10-Year Revenue Growth (%) Range
Min: -15   Max: 13.7
Current: -15

-15
13.7
EBITDA Growth (%) -21.20
ABT's EBITDA Growth (%) is ranked higher than
54% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ABT: -21.20 )
ABT' s 10-Year EBITDA Growth (%) Range
Min: -30   Max: 31.5
Current: -21.2

-30
31.5
EPS Growth (%) -20.40
ABT's EPS Growth (%) is ranked higher than
59% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ABT: -20.40 )
ABT' s 10-Year EPS Growth (%) Range
Min: -54   Max: 48.8
Current: -20.4

-54
48.8
» ABT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ABT Guru Trades in Q3 2013

Ray Dalio 118,700 sh (New)
Richard Pzena 6,449,283 sh (+49.22%)
PRIMECAP Management 16,188,865 sh (+36.9%)
Robert Olstein 145,000 sh (+12.4%)
Westport Asset Management 200,000 sh (+11.11%)
Mario Gabelli 93,801 sh (+9.59%)
Diamond Hill Capital 3,082,184 sh (+7.1%)
Bill Frels 338,861 sh (+4.32%)
John Buckingham 85,400 sh (+4.27%)
Murray Stahl 36,738 sh (+2.04%)
George Soros 1,054,252 sh (+1.93%)
Tom Russo 86,503 sh (+0.23%)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Robert Bruce 234,300 sh (unchged)
Jeff Auxier 80,490 sh (unchged)
Dodge & Cox 36,930 sh (-0.81%)
Pioneer Investments 2,028,687 sh (-1.14%)
Mason Hawkins 13,727,856 sh (-4.79%)
Jeremy Grantham 16,030,229 sh (-8.85%)
Ken Fisher 8,439 sh (-21.02%)
Manning & Napier Advisors, Inc 21,453 sh (-39.83%)
Steven Cohen 60,718 sh (-78.53%)
» More
Q4 2013

ABT Guru Trades in Q4 2013

Paul Tudor Jones 6,100 sh (New)
Daniel Loeb 3,250,000 sh (New)
Jim Simons 871,800 sh (New)
Mario Gabelli 197,183 sh (+110.21%)
Robert Olstein 179,000 sh (+23.45%)
Pioneer Investments 2,154,486 sh (+6.2%)
Bill Frels 351,373 sh (+3.69%)
Jeremy Grantham 16,154,651 sh (+0.78%)
John Buckingham 85,845 sh (+0.52%)
Diamond Hill Capital 3,088,381 sh (+0.2%)
Jeff Auxier 80,490 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Dodge & Cox 36,930 sh (unchged)
Tom Russo 86,503 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Ray Dalio Sold Out
PRIMECAP Management 16,135,908 sh (-0.33%)
Richard Pzena 6,426,564 sh (-0.35%)
Mason Hawkins 13,445,344 sh (-2.06%)
Robert Bruce 229,300 sh (-2.13%)
Murray Stahl 34,603 sh (-5.81%)
George Soros 970,181 sh (-7.97%)
Ken Fisher 7,645 sh (-9.41%)
Steven Cohen 5,622 sh (-90.74%)
» More
Q1 2014

ABT Guru Trades in Q1 2014

Louis Moore Bacon 10,998 sh (New)
Ray Dalio 17,200 sh (New)
Steven Cohen 156,100 sh (+2676.59%)
Diamond Hill Capital 5,984,714 sh (+93.78%)
George Soros 1,222,181 sh (+25.97%)
Ken Fisher 8,746 sh (+14.4%)
Richard Pzena 6,934,282 sh (+7.9%)
PRIMECAP Management 17,087,028 sh (+5.89%)
John Buckingham 88,280 sh (+2.84%)
Mason Hawkins 13,747,344 sh (+2.25%)
Robert Olstein 182,000 sh (+1.68%)
Jeremy Grantham 16,360,821 sh (+1.28%)
Murray Stahl 34,903 sh (+0.87%)
Dodge & Cox 36,950 sh (+0.05%)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Jeff Auxier 80,490 sh (unchged)
Tom Russo 86,503 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Daniel Loeb Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Bill Frels 343,865 sh (-2.14%)
Pioneer Investments 2,002,948 sh (-7.03%)
Mario Gabelli 168,487 sh (-14.55%)
» More
Q2 2014

ABT Guru Trades in Q2 2014

Paul Tudor Jones 25,430 sh (New)
Jean-Marie Eveillard 1,665,688 sh (New)
Jim Simons 1,503,700 sh (New)
Ken Fisher 18,027 sh (+106.12%)
Diamond Hill Capital 6,422,284 sh (+7.31%)
Bill Frels 368,808 sh (+7.25%)
Richard Pzena 7,197,691 sh (+3.8%)
Ray Dalio 17,700 sh (+2.91%)
John Buckingham 89,447 sh (+1.32%)
PRIMECAP Management 17,127,063 sh (+0.23%)
Westport Asset Management 200,000 sh (unchged)
Louis Moore Bacon 10,998 sh (unchged)
Robert Olstein 182,000 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Tom Russo 86,503 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Dodge & Cox 36,898 sh (-0.14%)
Mason Hawkins 13,687,877 sh (-0.43%)
Pioneer Investments 1,990,174 sh (-0.64%)
Jeff Auxier 79,671 sh (-1.02%)
Murray Stahl 34,303 sh (-1.72%)
Mario Gabelli 160,707 sh (-4.62%)
George Soros 932,181 sh (-23.73%)
Jeremy Grantham 11,956,508 sh (-26.92%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 New Buy0.16%$37.02 - $41 $ 42.117%1665688
George Soros 2014-06-30 Reduce -23.73%0.11%$37.02 - $41 $ 42.117%932181
Daniel Loeb 2014-03-31 Sold Out 2.1%$35.85 - $40.12 $ 42.119%0
George Soros 2014-03-31 Add 25.97%0.1%$35.85 - $40.12 $ 42.119%1222181
Ray Dalio 2014-03-31 New Buy0.01%$35.85 - $40.12 $ 42.119%17200
Daniel Loeb 2013-12-31 New Buy2.1%$33.01 - $38.71 $ 42.1114%3250000
Ray Dalio 2013-12-31 Sold Out 0.03%$33.01 - $38.71 $ 42.1114%0
Mario Gabelli 2013-12-31 Add 110.21%0.02%$33.01 - $38.71 $ 42.1114%197183
PRIMECAP Management 2013-09-30 Add 36.9%0.19%$32.93 - $36.88 $ 42.1120%16188865
Mason Hawkins 2013-09-30 Reduce -4.79%0.12%$32.93 - $36.88 $ 42.1120%13727856
Ray Dalio 2013-09-30 New Buy0.03%$32.93 - $36.88 $ 42.1120%118700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Abbott Laboratories

Lountzis Asset Management Comments on Abbott Laboratories - Mar 21, 2014

ABBOTT LABORATORIES (ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products.



On January 1, 2013, Abbott consummated the separation of its research based pharmaceuticals business and distributed 100% of the outstanding shares of common stock of AbbVie to the holders of record of Abbott common shares that were issued and outstanding on December 12, 2012. Each Abbot shareholder received one share of AbbVie common stock for every share of Abbot common stock held. The Abbott shareholder also received cash in lieu of any fractional share of AbbVie common stock resulting from the distribution.



Abbott common shares now trade under ticker symbol "ABT" and shares of AbbVie common stock trade under ticker symbol "ABBV". The new Abbott is a diversified global healthcare company with several leading franchises. In 2012, the company generated sales of $21.5 billion from these four diverse business units: nutritionals 30%, medical products 25%, established pharmaceuticals 24% and diagnostics 20%.



Abbott has leading market share positions in several businesses including the number one market share in:



1. Worldwide Adult Nutrition and U.S. Pediatric Nutrition



2. Amino Acid Immunoassay Diagnostics and Blood Screening



3. Drug Eluting Stents and for



4. Lasik



Furthermore, Abbott, in addition to a broad portfolio of products and services, is geographically diverse with 29% of sales in the U.S., 30% in other developed markets and 40% in the more rapidly growing emerging markets. The current Chairman and CEO, Miles D. White, will continue in these positions for the new Abbott, focused upon several initiatives including expanding the company’s products into new geographic markets, developing new technologies and focusing on accelerating margin expansion and improving free cash flow.



The new Abbott generated 2013 revenue through its four segments of $21.9 billion with earnings per share of $2.01. We continue to hold the new Abbott and believe its product and geographic diversity, combined with its leadership positions in several areas, will enable the company to continue to grow and prosper.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Diamond Hill Capital Comments on Abbott Laboratories - Jan 15, 2014

Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Abbott Laboratories

Lountzis Asset Management Comments on Abbott Laboratories
ABBOTT LABORATORIES (ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products. Read more...
Diamond Hill Capital Comments on Abbott Laboratories
Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.60
ABT's P/E(ttm) is ranked higher than
79% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.60 vs. ABT: 27.60 )
ABT' s 10-Year P/E(ttm) Range
Min: 5.76   Max: 28.46
Current: 27.6

5.76
28.46
P/B 2.78
ABT's P/B is ranked higher than
68% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.42 vs. ABT: 2.78 )
ABT' s 10-Year P/B Range
Min: 1.39   Max: 3.06
Current: 2.78

1.39
3.06
P/S 2.99
ABT's P/S is ranked higher than
61% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.45 vs. ABT: 2.99 )
ABT' s 10-Year P/S Range
Min: 0.96   Max: 3.1
Current: 2.99

0.96
3.1
PFCF 31.90
ABT's PFCF is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ABT: 31.90 )
ABT' s 10-Year PFCF Range
Min: 4.38   Max: 32.61
Current: 31.9

4.38
32.61
EV-to-EBIT 25.85
ABT's EV-to-EBIT is ranked higher than
79% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. ABT: 25.85 )
ABT' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 32.4
Current: 25.85

6.7
32.4
Shiller P/E 13.34
ABT's Shiller P/E is ranked higher than
95% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ABT: 13.34 )
ABT' s 10-Year Shiller P/E Range
Min: 8.15   Max: 15.13
Current: 13.34

8.15
15.13
Current Ratio 1.76
ABT's Current Ratio is ranked higher than
61% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ABT: 1.76 )
ABT' s 10-Year Current Ratio Range
Min: 0.75   Max: 2.36
Current: 1.76

0.75
2.36
Quick Ratio 1.49
ABT's Quick Ratio is ranked higher than
66% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.77 vs. ABT: 1.49 )
ABT' s 10-Year Quick Ratio Range
Min: 0.55   Max: 2.07
Current: 1.49

0.55
2.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
ABT's Dividend Yield is ranked higher than
70% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. ABT: 1.90 )
ABT' s 10-Year Dividend Yield Range
Min: 1.41   Max: 7.9
Current: 1.9

1.41
7.9
Dividend Payout 0.52
ABT's Dividend Payout is ranked higher than
74% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ABT: 0.52 )
ABT' s 10-Year Dividend Payout Range
Min: 0.23   Max: 2.53
Current: 0.52

0.23
2.53
Dividend growth (3y) -31.20
ABT's Dividend growth (3y) is ranked higher than
62% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.10 vs. ABT: -31.20 )
ABT' s 10-Year Dividend growth (3y) Range
Min: -31.2   Max: 12.6
Current: -31.2

-31.2
12.6
Yield on cost (5-Year) 0.73
ABT's Yield on cost (5-Year) is ranked lower than
70% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. ABT: 0.73 )
ABT' s 10-Year Yield on cost (5-Year) Range
Min: 0.55   Max: 3.06
Current: 0.73

0.55
3.06
Share Buyback Rate -0.40
ABT's Share Buyback Rate is ranked higher than
79% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. ABT: -0.40 )
ABT' s 10-Year Share Buyback Rate Range
Min: 0.8   Max: -0.8
Current: -0.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.12
ABT's Price/Tangible Book is ranked lower than
53% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. ABT: 8.12 )
ABT' s 10-Year Price/Tangible Book Range
Min: 2.87   Max: 427.6
Current: 8.12

2.87
427.6
Price/DCF (Projected) 0.85
ABT's Price/DCF (Projected) is ranked higher than
97% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.80 vs. ABT: 0.85 )
ABT' s 10-Year Price/DCF (Projected) Range
Min: 0.36   Max: 1.3
Current: 0.85

0.36
1.3
Price/Median PS Value 2.04
ABT's Price/Median PS Value is ranked higher than
73% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. ABT: 2.04 )
ABT' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 1.87
Current: 2.04

0.67
1.87
Price/Graham Number 3.28
ABT's Price/Graham Number is ranked higher than
67% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. ABT: 3.28 )
ABT' s 10-Year Price/Graham Number Range
Min: 1.07   Max: 20.52
Current: 3.28

1.07
20.52
Earnings Yield (Greenblatt) 3.90
ABT's Earnings Yield (Greenblatt) is ranked higher than
65% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. ABT: 3.90 )
ABT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 15
Current: 3.9

3.1
15
Forward Rate of Return (Yacktman) -14.89
ABT's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ABT: -14.89 )
ABT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.3   Max: 32.2
Current: -14.89

-2.3
32.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:ABT.UK, ABT.Switzerland, ABL.Germany
Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells a broad and diversified line of health care products. It has five reportable revenue segments, Proprietary Pharmaceutical Products, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Proprietary Pharmaceutical Products include Humira, for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease; TriCor, Trilipix, Simcor, and Niaspan, for the treatment of dyslipidemia; Kaletra, also marketed as Aluvia, and Norvir, protease inhibitors for the treatment of HIV infection. Established Pharmaceutical Products include Creon, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis; Influvac, an influenza vaccine available during flu season; Serc, for the treatment of Ménière's disease and vestibular vertigo; Brufen, for the treatment of pain, fever and inflammation. Diagnostic Products include immunoassay and clinical chemistry systems, including ARCHITECT and ABBOTT PRISM; the m2000, an instrument that automates the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents including HIV, HBV, HCV, HPV, and CT/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit; the UroVysion bladder cancer recurrence kit; and the Vysis ALK Break Apart FISH Probe Kit, the only FDA-approved companion diagnostic to Pfizer's approved non-small-cell lung cancer therapy XALKORI. Nutritional Products include various forms of prepared infant formula and follow-on formula, including SimilacAdvance, Similac Advance with EarlyShield, Similac, Similac with Iron, Similac Sensitive, Similac Sensitive RS, Similac Go&Grow, Similac NeoSure, Similac Organic, Similac Special Care, Similac Total Comfort, Isomil Advance, Isomil, Alimentum, Gain, and Grow; adult and other pediatric nutritional products, including Ensure, Ensure Plus, Ensure Muscle Health, Ensure (with Nutrivigor), Glucerna, Glucerna Hunger Smart, PediaSure, PediaSure Sidekicks, EleCare, Juven, Abound, and Pedialyte; nutritional products used in enteral feeding in health care institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego (Enteral Pump) and Freego sets, and Nepro; and Zone Perfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge. Vascular Products include, Xience Xpedition, Xience Prime, Xience nano, and Xience V, drug-eluting stent systems developed on the Multi-Link Vision platform; Multi-Link 8, Multi-Link Vision and Multi-Link Mini Vision, coronary metallic stents; TREK and Voyager, balloon dilatation products; Absorb, a drug-eluting bioresorbable vascular scaffold.
» More Articles for ABT

Headlines

Articles On GuruFocus.com
6 Stocks Currently Trading Below Fair Value Jul 02 2014 
Why I Bought Baxter International Jun 19 2014 
Two Stocks On My Watch List For June 2014 May 29 2014 
Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 
Different Opinions on Bio-Rad Laboratories Apr 03 2014 
Absolute and Relative Valuation Models Indicate the Same: Abbot Is a Buy Mar 31 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Lountzis Asset Management Comments on Abbott Laboratories Mar 21 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 


More From Other Websites
Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf Aug 22 2014
Abbott Joins Forces with U.S. Department of Defense to Develop Portable Blood Tests for Evaluating... Aug 18 2014
Abbott, AbbVie Win Dismissal of Suit Over Depakote Marketing Aug 15 2014
ABBOTT LABORATORIES Financials Aug 12 2014
Access to Abbott's MitraClip® System Expands in the U.S. with Medicare National Coverage... Aug 12 2014
Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View Aug 07 2014
Drug company won't appeal gay rights ruling to top U.S. court Aug 05 2014
Delamaide: Tax issue shows Congress' failure Aug 05 2014
ABBOTT LABORATORIES Files SEC form 10-Q, Quarterly Report Aug 05 2014
[video] Cramer's stocks to watch: KORS Aug 04 2014
Charles R. Kummeth, the President and CEO of Bio-Techne (TECH), Interviews with The Wall Street... Aug 01 2014
Can Obamacare case jump right to Supreme Court? Aug 01 2014
How Obama Could End Walgreen's Tax-Inversion Hopes Jul 28 2014
3 Stocks Pushing The Health Services Industry Lower Jul 28 2014
Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association... Jul 28 2014
Top Trade Ideas for the Week of July 28, 2014: The Rest Jul 27 2014
Obama calls on Congress to end inversion deals, NY Times reports Jul 25 2014
Did Congress prescribe Obamacare a 'poison pill?' Jul 24 2014
Abbott Introduces New Similac® Breastfeeding Supplement with DHA, Lutein and Vitamin E Jul 24 2014
GlaxoSmithKline Slumps: GSK Falls 5.9% in Session Jul 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide